Competing interests
W.W., Cancer
ONCOLOGY, CANCER
Y.-L.W. was a research consultant for AstraZeneca, and received research funding from Roche and speech honoraria from AstraZeneca, Roche, Eli Lilly, Pfizer, and Sanofi. W.-Z.Z. received speech honoraria from AstraZeneca, Roche, Eli Lilly, and Pfizer. H.-R.L., K.L., and W.W. are employees of Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis and the Berry Oncology Corporation. All remaining authors declare no competing interests.